What is it about?
Letter to editor published in "American Journal of Transplantation"
Featured Image
Why is it important?
If clinical manifestation and lung injury of COVID-19 are in part mediated by overactivation of T cells immune response, data reported in the literature suggests that clinical conditions associated with impairment in T-cell response, like immunosuppression in solid organ transplanted patients, could alter the clinical course and reduced the rate and severity of lung injury. Although transplanted patients could be more susceptible to SARS-CoV-2 infection with atypical manifestations, the chronic use of immunosuppressive drugs could represent a “protective factor” for the serious clinical complication of the disease. This hypothesis could also explain why patients with lymphopenia are those with the worst outcomes. Lymphopenia could be caused by lung sequestration of hyperactivated T-cell and immunodepression drug-related could limit this effect.
Perspectives
Actually, except for the case reports , we found no data about the incidence and outcome of COVID-19 in this cluster of patients. Furthermore, immunosuppressive drugs could be a valid “therapeutic” choice, reducing the activity of the T-cell immune system and preventing organ injury.
MD Antonio Romanelli
AOU San Giovanni di Dio e Ruggi D’Aragona
Read the Original
This page is a summary of: Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis, Arabian archaeology and epigraphy, April 2020, Wiley,
DOI: 10.1111/ajt.15905.
You can read the full text:
Contributors
The following have contributed to this page
